

Pedro Campos (1); Laila Viana (2);

(1) - Hospital Fernando Fonseca, Nefrologia, Amadora, Portugal;

(2) - Hospital do Rim, Transplantação, São Paulo, Brasil;

INTRODUCTION AND AIMS

Renal transplant recipients may present with intracranial space-occupying lesions (SOLs) due to infections (opportunistic or not) as well as a post-transplant lymphoproliferative disorder (PTLD) therefore SOL in this population constitute a diagnostic challenge. We aimed to characterize the patients with SOL at our center

METHODS

Study design: Cross sectional study

Setting: Outpatient Kidney transplant recipients

Population studied: Adult renal transplant recipients who had a stereotaxic brain biopsy performed between January 2014 and December 2015

Exclusion criteria: <18 years old; CKD 5D

Primary endpoint: Space occupying brain lesions

Definitions: Renal function was evaluated by the CKD-EPI Equation.

Data collection: Demographic, clinical and laboratorial data was registered and collected into a database until the end of follow-up.

Statistic Analysis. Data is presented as mean \pm SD or median and interquartile range (IQR) for continuous variables.

RESULTS

Demographics

- n = 13 patients (6♂, 7 ♀),
- Mean age = 45 \pm 8 anos
- Time after transplant = 6,6 \pm 3,4 anos
- Median eGFR 86.4mL/min (IQR 74-98)
- Live donor – 23,1% (n = 3)
- Primary Complaint:
 - Decreased consciousness – 46,1%
 - Headache – 38,5%
 - Focal neurologic signs – 15,4%

+ Fever – 38,5%

Diagnoses

- Infection (7 cases) - 5,7 \pm 3years
 - Fungal (3)
 - Mycobact. (2)
 - Bact. (2)
- PTLD (5 cases) - 7 \pm 3,9 years
 - B-cell lymphoma (EBV in Liquor positive in 40% of the patients)
- Primary CNS tumour (1 case) - 9 years
 - Astrocytoma
- Immunossuppression
 - FK & MPS 76,9% (10 cases – inc. 3 live-donors)
 - FK & AZA 23,1% (2 cases)

CONCLUSIONS

Cerebral SOLs are a rare but serious finding after kidney transplant. No clinical features appear accurate to estimate de lesion etiology. A high suspicion index is required and a biopsy of the lesion is vital for appropriate diagnosis and management.

REFERENCES

- Mentzer SJ, Perrine SP, Faller DV. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. *Transpl Infect Dis* (2001) 3(3):177-85.